Mechanistic insights toward progress in alogliptin beyond glycemic control: translational perspective
Abstract Background Alogliptin belongs to gliptin family of drugs that inhibits ubiquitous enzyme dipeptidyl peptidase-4 (DPP-4). Gliptins increase the life-span of incretin hormones that appear to benefit functioning of several organs via various signaling pathways. Main body Alogliptin is approved...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-02-01
|
| Series: | Beni-Suef University Journal of Basic and Applied Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43088-025-00601-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823861720720867328 |
|---|---|
| author | Faraha Ahmed Syed Sufian Ahmad M. Mumtaz Alam M. Shaqiquzzaman Abul Kalam Najmi Mohammad Ahmed Khan |
| author_facet | Faraha Ahmed Syed Sufian Ahmad M. Mumtaz Alam M. Shaqiquzzaman Abul Kalam Najmi Mohammad Ahmed Khan |
| author_sort | Faraha Ahmed |
| collection | DOAJ |
| description | Abstract Background Alogliptin belongs to gliptin family of drugs that inhibits ubiquitous enzyme dipeptidyl peptidase-4 (DPP-4). Gliptins increase the life-span of incretin hormones that appear to benefit functioning of several organs via various signaling pathways. Main body Alogliptin is approved for treatment of type 2 diabetes mellitus (T2DM) in majority of the countries. It is administered orally and efficacious as monotherapy as well as combined therapy with other T2DM drugs, such as pioglitazone and metformin. It has a good safety profile, well-tolerated in elderly patients and in patients with co-morbid conditions including risks of cardiovascular event, renal or hepatic insufficiency. Therefore, alogliptin is incessantly experimented and investigated for its therapeutic benefit. Recent developments have indicated potential of alogliptin in discrete pathological conditions. Emerging evidences suggest prominent cardioprotective, hepatoprotective, reno-protective, anti-inflammatory and lipid-lowering capacity of alogliptin. Apart from inhibiting DPP-4 enzyme, alogliptin also affects several signaling mechanisms to exhibit protective effects in patients with diabetes-induced complications. Conclusion This review highlights the potential role of alogliptin and mechanisms involved in amelioration of several other pathological conditions apart from its role in glucose metabolism. Thus, this may provide insights for better utilization and repurposing of alogliptin as a therapeutic agent. |
| format | Article |
| id | doaj-art-57d4fd08e74346feb5d12c760eb45234 |
| institution | Kabale University |
| issn | 2314-8543 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Beni-Suef University Journal of Basic and Applied Sciences |
| spelling | doaj-art-57d4fd08e74346feb5d12c760eb452342025-02-09T12:49:59ZengSpringerOpenBeni-Suef University Journal of Basic and Applied Sciences2314-85432025-02-0114111410.1186/s43088-025-00601-5Mechanistic insights toward progress in alogliptin beyond glycemic control: translational perspectiveFaraha Ahmed0Syed Sufian Ahmad1M. Mumtaz Alam2M. Shaqiquzzaman3Abul Kalam Najmi4Mohammad Ahmed Khan5Department of Pharmacology, School of Pharmaceutical Education and Research (SPER), Jamia HamdardDepartment of Pharmacology, School of Pharmaceutical Education and Research (SPER), Jamia Hamdard2Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard2Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia HamdardDepartment of Pharmacology, School of Pharmaceutical Education and Research (SPER), Jamia HamdardDepartment of Pharmacology, School of Pharmaceutical Education and Research (SPER), Jamia HamdardAbstract Background Alogliptin belongs to gliptin family of drugs that inhibits ubiquitous enzyme dipeptidyl peptidase-4 (DPP-4). Gliptins increase the life-span of incretin hormones that appear to benefit functioning of several organs via various signaling pathways. Main body Alogliptin is approved for treatment of type 2 diabetes mellitus (T2DM) in majority of the countries. It is administered orally and efficacious as monotherapy as well as combined therapy with other T2DM drugs, such as pioglitazone and metformin. It has a good safety profile, well-tolerated in elderly patients and in patients with co-morbid conditions including risks of cardiovascular event, renal or hepatic insufficiency. Therefore, alogliptin is incessantly experimented and investigated for its therapeutic benefit. Recent developments have indicated potential of alogliptin in discrete pathological conditions. Emerging evidences suggest prominent cardioprotective, hepatoprotective, reno-protective, anti-inflammatory and lipid-lowering capacity of alogliptin. Apart from inhibiting DPP-4 enzyme, alogliptin also affects several signaling mechanisms to exhibit protective effects in patients with diabetes-induced complications. Conclusion This review highlights the potential role of alogliptin and mechanisms involved in amelioration of several other pathological conditions apart from its role in glucose metabolism. Thus, this may provide insights for better utilization and repurposing of alogliptin as a therapeutic agent.https://doi.org/10.1186/s43088-025-00601-5AlogliptinCardioprotectiveAnti-inflammatoryNephroprotectiveHepatoprotective |
| spellingShingle | Faraha Ahmed Syed Sufian Ahmad M. Mumtaz Alam M. Shaqiquzzaman Abul Kalam Najmi Mohammad Ahmed Khan Mechanistic insights toward progress in alogliptin beyond glycemic control: translational perspective Beni-Suef University Journal of Basic and Applied Sciences Alogliptin Cardioprotective Anti-inflammatory Nephroprotective Hepatoprotective |
| title | Mechanistic insights toward progress in alogliptin beyond glycemic control: translational perspective |
| title_full | Mechanistic insights toward progress in alogliptin beyond glycemic control: translational perspective |
| title_fullStr | Mechanistic insights toward progress in alogliptin beyond glycemic control: translational perspective |
| title_full_unstemmed | Mechanistic insights toward progress in alogliptin beyond glycemic control: translational perspective |
| title_short | Mechanistic insights toward progress in alogliptin beyond glycemic control: translational perspective |
| title_sort | mechanistic insights toward progress in alogliptin beyond glycemic control translational perspective |
| topic | Alogliptin Cardioprotective Anti-inflammatory Nephroprotective Hepatoprotective |
| url | https://doi.org/10.1186/s43088-025-00601-5 |
| work_keys_str_mv | AT farahaahmed mechanisticinsightstowardprogressinalogliptinbeyondglycemiccontroltranslationalperspective AT syedsufianahmad mechanisticinsightstowardprogressinalogliptinbeyondglycemiccontroltranslationalperspective AT mmumtazalam mechanisticinsightstowardprogressinalogliptinbeyondglycemiccontroltranslationalperspective AT mshaqiquzzaman mechanisticinsightstowardprogressinalogliptinbeyondglycemiccontroltranslationalperspective AT abulkalamnajmi mechanisticinsightstowardprogressinalogliptinbeyondglycemiccontroltranslationalperspective AT mohammadahmedkhan mechanisticinsightstowardprogressinalogliptinbeyondglycemiccontroltranslationalperspective |